Mariuzza R, Singh P, Karade S, Shahid S, Sharma V
Immunol Rev. 2025; 329(1):e13435.
PMID: 39748148
PMC: 11695704.
DOI: 10.1111/imr.13435.
Fuchs K, Goransson M, Kester M, Ettienne N, van de Meent M, de Jong R
J Immunother Cancer. 2024; 12(12).
PMID: 39653555
PMC: 11629015.
DOI: 10.1136/jitc-2024-009564.
Rafiei A, Gualandi M, Yang C, Woods R, Kumar A, Brunner K
Cancers (Basel). 2024; 16(16).
PMID: 39199672
PMC: 11352577.
DOI: 10.3390/cancers16162902.
Palvair J, Farhat I, Chaintreuil M, Dal Zuffo L, Messager L, Tinel C
Transpl Int. 2024; 37:12995.
PMID: 39010891
PMC: 11247310.
DOI: 10.3389/ti.2024.12995.
Tsuneyoshi N, Hosoya T, Takeno Y, Saitoh K, Murai H, Amimoto N
Stem Cell Res Ther. 2024; 15(1):193.
PMID: 38956724
PMC: 11218117.
DOI: 10.1186/s13287-024-03810-4.
CRISPR-Cas9 screening reveals a distinct class of MHC-I binders with precise HLA-peptide recognition.
Schoufour T, van der Plas-van Duijn A, Derksen I, Melgers M, van Veenendaal J, Lensen C
iScience. 2024; 27(6):110120.
PMID: 38939106
PMC: 11209011.
DOI: 10.1016/j.isci.2024.110120.
A new mechanism of antibody diversity: formation of the natural antibodies containing LAIR1 and LILRB1 extracellular domains.
Chen Y, Zeng Z, Chen Z, Yuan N, Ye X, Zhang C
Antib Ther. 2024; 7(2):157-163.
PMID: 38933531
PMC: 11200687.
DOI: 10.1093/abt/tbae008.
MHC1/LILRB1 axis as an innate immune checkpoint for cancer therapy.
Hu Z, Zhang Q, He Z, Jia X, Zhang W, Cao X
Front Immunol. 2024; 15:1421092.
PMID: 38911856
PMC: 11190085.
DOI: 10.3389/fimmu.2024.1421092.
Uncloaking the viral glycocalyx: How do viruses exploit glycoimmune checkpoints?.
Domma A, Henderson L, Nurdin J, Kamil J
Adv Virus Res. 2024; 119:63-110.
PMID: 38897709
PMC: 11192240.
DOI: 10.1016/bs.aivir.2024.03.001.
LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development.
Huang R, Liu X, Kim J, Deng H, Deng M, Gui X
Cancer Immunol Res. 2023; 12(3):350-362.
PMID: 38113030
PMC: 10932818.
DOI: 10.1158/2326-6066.CIR-23-0496.
Bw4 ligand and direct T-cell receptor binding induced selection on HLA A and B alleles.
Levi R, Levi L, Louzoun Y
Front Immunol. 2023; 14:1236080.
PMID: 38077375
PMC: 10703150.
DOI: 10.3389/fimmu.2023.1236080.
Overall avidity declines in TCR repertoires during latent CMV but not EBV infection.
Couturaud B, Doix B, Carretero-Iglesia L, Allard M, Pradervand S, Hebeisen M
Front Immunol. 2023; 14:1293090.
PMID: 38053994
PMC: 10694213.
DOI: 10.3389/fimmu.2023.1293090.
Human leukocyte immunoglobulin-like receptors in health and disease.
Redondo-Garcia S, Barritt C, Papagregoriou C, Yeboah M, Frendeus B, Cragg M
Front Immunol. 2023; 14:1282874.
PMID: 38022598
PMC: 10679719.
DOI: 10.3389/fimmu.2023.1282874.
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
Zeller T, Munnich I, Windisch R, Hilger P, Schewe D, Humpe A
Front Immunol. 2023; 14:1240275.
PMID: 37781391
PMC: 10533923.
DOI: 10.3389/fimmu.2023.1240275.
Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.
Meazza R, Ruggeri L, Guolo F, Minetto P, Canevali P, Loiacono F
Front Immunol. 2023; 14:1111419.
PMID: 36865545
PMC: 9971917.
DOI: 10.3389/fimmu.2023.1111419.
Immune Checkpoint and Other Receptor-Ligand Pairs Modulating Macrophages in Cancer: Present and Prospects.
Yang Y, Zhang W, Lan P
Cancers (Basel). 2022; 14(23).
PMID: 36497444
PMC: 9736575.
DOI: 10.3390/cancers14235963.
Distinct frequency patterns of LILRB3 and LILRA6 allelic variants in Europeans.
Bashirova A, Kasprzak W, OhUigin C, Carrington M
Immunogenetics. 2022; 75(3):263-267.
PMID: 36449053
PMC: 10205885.
DOI: 10.1007/s00251-022-01286-1.
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T, Lutz S, Munnich I, Windisch R, Hilger P, Herold T
Front Immunol. 2022; 13:929339.
PMID: 36389667
PMC: 9647079.
DOI: 10.3389/fimmu.2022.929339.
Variants of HCMV Sequenced Directly from Clinical Specimens Associate with Antibody and T-Cell Responses to HCMV.
Waters S, Lee S, Ariyanto I, Leary S, Munyard K, Gaudieri S
Int J Mol Sci. 2022; 23(21).
PMID: 36361707
PMC: 9658343.
DOI: 10.3390/ijms232112911.
Identification of hub genes and pathophysiological mechanism related to acute unilateral vestibulopathy by integrated bioinformatics analysis.
Cheng Y, Zheng J, Zhan Y, Liu C, Lu B, Hu J
Front Neurol. 2022; 13:987076.
PMID: 36237611
PMC: 9552803.
DOI: 10.3389/fneur.2022.987076.